Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.   20 June 2013
Americas
A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.   17 June 2013
Americas
Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.   14 June 2013
Americas
The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.   13 June 2013
Asia-Pacific
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.   7 June 2013
Americas
Drug-maker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product, according to a patent settlement between the companies.   4 June 2013
Europe
The definition of what constitutes a co-pending patent filing in Europe has recently been rewritten to include patent applications from within the same patent family. Jane Wainwright of Potter Clarkson investigates the decisions leading to this change.   31 May 2013
Biotechnology
BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?   31 May 2013
Americas
Japanese pharma company Takeda has sued generic drug-makers Impax and Sandoz for allegedly infringing a patent directed to its anti-heartburn drug Dexilant.   31 May 2013
Americas
California-based biotechnology company Amgen has entered into a long-term partnership with Japanese pharmaceutical company Astellas Pharmas Inc to provide new medicines in Japan.   30 May 2013